Gastroesophageal Junction Adenocarcinoma

DBCOND0038020Digestive System DiseasesNeoplasms

Gastroesophageal Junction Adenocarcinoma is the indication for 1 drug in DrugBank. It is covered by 4 curated, structured indications.

Also known as
Adenocarcinoma of the Gastroesophageal Junction · Adenocarcinomas of the Gastroesophageal Junction · Adenocarcinoma of the Esophagogastric Junction · Esophagogastric Junction Adenocarcinoma · Adenocarcinoma of Esophagogastric Junction
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM0563030SNOMED CT276803003MedDRA10001173UMLSC0279628

What you can answer from here — as of October 22, 2026

1Indicated drugWith each drug's targets and mechanism
Listed above
4Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
435Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which approved drugs for Gastroesophageal Junction Adenocarcinoma share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In